EUVIMEDEUVIMED entdecken
Crossref

Neferine-enhanced Shenling Baizhu Tang potentiates anti-PD-1 therapy in colorectal cancer liver metastasis via CYP2E1–PPARα–mediated lipid reprogramming

Xiaochun Zhang, Yang Yang, Meiqi Zhang, Yanyan Xu, Jun Wang, Chunxia Zhang, Jiabo Gu, Jianlei Liu, Xiaorui Ye, Xinyi Zhang, Heiying Jin

Phytomedicine · 2026-07 · 156 · 158236

DOI: 10.1016/j.phymed.2026.158236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-07. Verfasst von Xiaochun Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, 210017, China; Department of Colorectal Surgery, the Second A…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, PPAR alpha, Drugs, Chinese Herbal, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Jiangsu Province Department of Science and Technology, Jiangsu Provincial Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors elicit responses in merely 20-40% of patients with microsatellite instability-high or mismatch repair-deficient colorectal cancer (CRC), making immunotherapy resistance a formidable clinical challenge. The immunosuppressive tumor microenvironment, characterized by regulatory T-cell accumulation and metabolic reprogramming, substantially drives this treatment failure. PURPOSE: To determine whether neferine, a bioactive alkaloid derived from the traditional Chinese medicine formulation Shenling Baizhu Tang (SLBZT), enhances anti-PD-1 (aPD-1) efficacy in CRC liver metastasis by modulating the CYP2E1-PPARα metabolic axis. METHODS: A CRC liver metastasis model was established via intrasplenic injection of MC38-Luc cells into C57BL/6 J mice. The animals were administered aPD-1 alone or in combination with low- or high-dose SLBZT. Tumor burden was evaluated via in vivo imaging and histopathology. Integrated transcriptomics and metabolomics, CRISPR-Cas9-mediated CYP2E1 knockout, T-cell coculture assays, alongside computational and biophysical analyses, were employed to elucidate the active components and underlying mechanisms. Evaluated functional outcomes included tumor burden, immune phenotyping, CYP2E1/PPARα signaling, and homovanillic acid (HVA) levels. RESULTS: High-dose SLBZT markedly augmented aPD-1-mediated suppression of CRC liver metastasis without compromising systemic tolerability. Multi-omics profiling coupled with genetic validation revealed that CYP2E1-driven lipid metabolic reprogramming and its downstream metabolite HVA serve as key mediators of regulatory T-cell expansion and CD8⁺ T-cell exhaustion. Both SLBZT and neferine diminished HVA accumulation, restored effector T-cell function, and potentiated aPD-1 efficacy. Furthermore, biophysical and computational analyses confirmed the direct inhibition of CYP2E1 by neferine. CONCLUSION: Neferine sensitizes tumors to PD-1 blockade by reprogramming lipid metabolism and remodeling the immune microenvironment via the CYP2E1-PPARα axis, highlighting its translational potential as a metabolic immunoadjuvant to overcome immunotherapy resistance in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPPAR alphaDrugs, Chinese HerbalLiver NeoplasmsBenzylisoquinolinesCytochrome P-450 CYP2E1Immune Checkpoint InhibitorsAnimalsMiceMice, Inbred C57BLMetabolic ReprogrammingMaleTumor MicroenvironmentLipid MetabolismHumansCell Line, TumorProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

CYP2E1Colorectal cancer liver metastasisNeferinePPARαShenling Baizhu Tang

Substanzen

PPAR alphaDrugs, Chinese HerbalneferineBenzylisoquinolinesCytochrome P-450 CYP2E1Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorBaizhu

Autor:innen und Institutionen

  • The Second Clinical Medical College of Nanjing University of Chinese Medicine, Nanjing, 210017, China; Department of Colorectal Surgery, the Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing,…
  • Department of Colorectal Surgery, the Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210017, China.

Förderung

  • Jiangsu Province Department of Science and Technology
  • Jiangsu Provincial Key Research and Development Program

Zitieren

APA

Zhang, X., Yang, Y., Zhang, M., Xu, Y., Wang, J., Zhang, C., Gu, J., Liu, J., Ye, X., Zhang, X., & Jin, H. (2026). Neferine-enhanced Shenling Baizhu Tang potentiates anti-PD-1 therapy in colorectal cancer liver metastasis via CYP2E1–PPARα–mediated lipid reprogramming. Phytomedicine, 156, 158236. https://doi.org/10.1016/j.phymed.2026.158236

Vancouver

Zhang X, Yang Y, Zhang M, Xu Y, Wang J, Zhang C, et al. Neferine-enhanced Shenling Baizhu Tang potentiates anti-PD-1 therapy in colorectal cancer liver metastasis via CYP2E1–PPARα–mediated lipid reprogramming. Phytomedicine. 2026;156:158236. doi:10.1016/j.phymed.2026.158236

BibTeX
@article{Zhang2026,
  author = {Zhang, Xiaochun and Yang, Yang and Zhang, Meiqi and Xu, Yanyan and Wang, Jun and Zhang, Chunxia and Gu, Jiabo and Liu, Jianlei and Ye, Xiaorui and Zhang, Xinyi and Jin, Heiying},
  title = {Neferine-enhanced Shenling Baizhu Tang potentiates anti-PD-1 therapy in colorectal cancer liver metastasis via CYP2E1–PPARα–mediated lipid reprogramming},
  journal = {Phytomedicine},
  year = {2026},
  volume = {156},
  pages = {158236},
  doi = {10.1016/j.phymed.2026.158236}
}
Kostenlos starten →